- Home
- YDDL vs SGMT Comparison
YDDL vs SGMT Comparison
Compare YDDL & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YDDL
- SGMT
- Stock Information
- Founded
- YDDL 2014
- SGMT 2006
- Country
- YDDL Philippines
- SGMT United States
- Employees
- YDDL N/A
- SGMT N/A
- Industry
- YDDL Industrial Specialties
- SGMT
- Sector
- YDDL Consumer Discretionary
- SGMT
- Exchange
- YDDL Nasdaq
- SGMT Nasdaq
- Market Cap
- YDDL 295.4M
- SGMT 238.7M
- IPO Year
- YDDL 2025
- SGMT 2023
- Fundamental
- Price
- YDDL $4.90
- SGMT $7.66
- Analyst Decision
- YDDL
- SGMT Strong Buy
- Analyst Count
- YDDL 0
- SGMT 7
- Target Price
- YDDL N/A
- SGMT $26.57
- AVG Volume (30 Days)
- YDDL 6.2M
- SGMT 559.5K
- Earning Date
- YDDL 01-01-0001
- SGMT 11-12-2025
- Dividend Yield
- YDDL N/A
- SGMT N/A
- EPS Growth
- YDDL 16.34
- SGMT N/A
- EPS
- YDDL 0.12
- SGMT N/A
- Revenue
- YDDL $53,463,785.00
- SGMT N/A
- Revenue This Year
- YDDL N/A
- SGMT N/A
- Revenue Next Year
- YDDL N/A
- SGMT N/A
- P/E Ratio
- YDDL $52.67
- SGMT N/A
- Revenue Growth
- YDDL 29.55
- SGMT N/A
- 52 Week Low
- YDDL $4.60
- SGMT $1.73
- 52 Week High
- YDDL $8.89
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- YDDL N/A
- SGMT 54.15
- Support Level
- YDDL N/A
- SGMT $7.11
- Resistance Level
- YDDL N/A
- SGMT $8.76
- Average True Range (ATR)
- YDDL 0.00
- SGMT 0.53
- MACD
- YDDL 0.00
- SGMT 0.15
- Stochastic Oscillator
- YDDL 0.00
- SGMT 52.33
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.